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The aim of this study was to investigate the antiobesity and antihyperlipidaemic eﬀects of emodin on high-fat diet (HFD)-induced
obese rats, and on the regulation of the expression of the genes involved in lipid metabolism to elucidate the mechanisms. After
being fed HFD for two weeks, Wistar rats were dosed orally with emodin (40 and 80mgkg−1) or pioglitazone (20mgkg−1),
once daily for eight weeks. Emodin (80mgkg−1 per day) displayed similar characteristics to pioglitazone (20mg kg−1 per day)
in reducing body weight gain, plasma lipid levels as well as coronary artery risk index and atherogenic index of HFD-fed rats.
Emodin also caused dose related reductions in the hepatic triglyceride and cholesterol contents and lowered hepatic lipid droplets
accumulation inHFD-fedrats.Emodinandpioglitazone enhanced thephosphorylationofAMP-activated proteinkinase(AMPK)
and its primary downstream targeting enzyme, acetyl-CoA carboxylase, up-regulated gene expression of carnitine palmitoyl
transferase 1, and down-regulated sterol regulatory element binding protein 1 and fatty acid synthase protein levels in hepatocytes
of HFD-fed rats. Our ﬁndings suggest emodin could attenuate lipid accumulation by decreasing lipogenesis and increasing
mitochondrial fatty acid β-oxidation mediated by activation of the AMPK signaling pathway.
1.Introduction
Obesity accelerates the accumulation of excessive fat, which
can cause chronic diseases in both humans and laboratory
animals such as diabetes mellitus, cardiovascular disease,
digestivedisease,respiratorydisease,andvariouscancers[1].
Totreatandcontrolobesity,besidesdiettherapyandexercise,
many diﬀerent approaches such as drugs for weight loss or
loss of appetite and food supplements are suggested to date.
However, most antiobesity drugs have been withdrawn from
the market based on U.S. FDA warnings of serious adverse
reactions [2]. There is growing interest in herbal remedies
due to the side eﬀects associated with current antiobesity
agents,becausetheplantkingdomisawideﬁeldtosearchfor
natural eﬀective antiobesity agents with less signiﬁcant side
eﬀects. In line with this, we used oriental medicinal herbs
that had been expected to have a lipid lowering eﬀect based
on the previous reports [3].
Emodin (1,3,8-trihydroxy-6-methylanthraquinone), an
important component of rhubarb, a traditional Chinese
herb, exerts an obvious antiinﬂammatory [4, 5]a n da n t i -
oxidative eﬀects [6, 7]. Emodin could prevent the formation
andprogressofatherosclerosisbyinhibitingtheproliferation
of human vascular smooth muscle cells and reducing the
plasma concentration of malondialdehyde and oxidized
low density lipoprotein [8]. That emodin ameliorated the
glucose tolerance and improved insulin sensitivity through
the activation of peroxisome-proliferator-activated receptor2 Evidence-Based Complementary and Alternative Medicine
(PPAR)γ similar to thiazolidinediones (TZD) on diabetic
mice has been proved [9]. Actually, the fact that TZD
activates AMP-activated protein kinase (AMPK) to stimulate
the pathways that increase energy production, such as
glucose transport and fatty acid oxidation, and switches
oﬀ the pathways that consume energy such as lipogenesis,
protein have been identiﬁed [10]. Although emodin has
also been found to be eﬀective in fatty liver associated with
increasing the expression of hepatic PPARγ [11], insuﬃcient
information is available regarding the mechanism related to
AMPKsignalingpathwayontheregulationoflipiddisorders.
It is well known that high-fat diets (HFDs) are respon-
sible for high global prevalence of obesity [12]. Rodents fed
a lard-based HFD showed visceral adiposity, hyperglycemia,
dyslipidemia, hyperinsulinemia, and hepatic steatosis, which
are distinctly linked with human obesity [13]. This study
investigated the eﬀects of emodin on lipid metabolism in
HFD-fed rats and sought possible mechanisms of action.
2. Methods
2.1. Animal Models and Treatment Protocols. Male Wistar
rats aged 8 weeks were obtained from the National Labora-
tory Animal Center (Taipei, Taiwan). They were maintained
in a temperature-controlled room (25 ± 1◦C) and kept on
a 12:12 light-dark cycle (lights on at 06:00h) in our animal
center. Food and water were available ad libitum. Regular rat
diet (RCD) (11kcal% fat #LM-485, Teklad, Madison, WI)
was used as the maintenance and control diet. A puriﬁed
ingredient HFD with 45kcal% fat primarily from lard (no.
D12451, Research Diets, New Brunswick, NJ) was used to
induce a rapid increase in body weight (BW) and obesity
[14]. The caloric density of the control diet was 3.4kcal g−1;
that of the HFD was 4.73kcal g−1, resulting in lower daily
food consumption in grams for the rats fed the HFD. All
animal procedures were performed according to the Guide
for the Care and Use of Laboratory Animals of the National
Institutes of Health, as well as the guidelines of the Animal
Welfare Act (approval number: IACUC 99-16; approval date:
September 9, 2010).
After being fed an HFD for 2 weeks, emodin (purity
≥97.0%; Sigma-Aldrich Co.; Cat. no. 30269) was dissolved
in distilled water for oral gavage administration at the
desired doses (40 and 80mg kg−1 per day) in a volume of
2mL kg −1 once a day into the HFD-fed rats. The dose of
emodin chosen was according to previous study indicated
that emodin at an oral dose of 40mg kg−1 was eﬀective in
themurine nonalcoholicfattyliver(NAFLD)treatment[11].
Another group of HFD-fed was treated by oral gavage with
pioglitazone hydrochloride (Takeda Pharmaceutical Co. Ltd.
Osaka, Japan: 20mg kg−1 per day) [15]. A further group of
HFD-fed and RCD-fed rats were treated similarly but with
the same volume of vehicle (distilled water) as was used to
dissolve the tested compounds during the same treatment
period. Water was made available ad libitum throughout the
experiment.
Eight weeks after the treatment, rats were weighed and
blood samples were collected from the lateral tail vein of
the animals anesthetized with sodium pentobarbital (30mg
kg−1) administered intraperitoneally (i.p.). Samples were
centrifuged at 2,000×g for 10 minutes at 4◦C. The plasma
was then removed and placed into aliquots for the respective
analytical determinations. Livers were removed after blood
was collected, rinsed with a physiological saline solution,
weighed, and immediately stored at −70◦C.
2.2. Biochemical Parameter Analysis. The diagnostic kits for
determinations for plasma glucose (Cat. no. 10009582),
total cholesterol (TC; Cat. no. 10007640) and triglyceride
(TG; Cat. no. 10010303) were purchased from Cayman
Chemical Company (Michigan, USA). The diagnostic kit
for determinations for plasma levels of high -density
lipoprotein cholesterol (HDL-c) was purchased from Bio-
Quant Diagnostics (CA, USA; Cat. No. BQ 019CR), low-
density lipoprotein cholesterol (LDL-c) were calculated by
using Friedewald’s equation [16]. Plasma level of free fatty
acids (FFAs) was determined by the FFAs quantiﬁcation kit
obtained from Abcam plc. (MA, USA; Cat. No. ab65341).
All samples were analyzed in triplicate. Atherogenic index
(AI) and coronary risk index (CRI) were calculated as: LDL-
c/HDL-c and TC/HDL-c [17, 18], respectively.
2.3. Extraction of Hepatic Lipids. After removal from the
animals, part of the samples of fresh liver were collected for
analyzing the lipid contained. Liver (1.25g) was homoge-
nized with chloroform/methanol (1:2, 3.75mL), and then
chloroform (1.25mL) and distilled water (1.25mL) were
added to the homogenate and mixed well. After centrifu-
gation (1,500×g for 10min), the lower clear organic
phase solution was transferred into a new glass tube and
then lyophilized. The lyophilized powder was dissolved in
chloroform/methanol (1:2) as the hepatic lipid extracts and
stored at −20◦C for less than 3 days [19]. The hepatic
cholesterolandtriglycerideinthelipidextractswereanalyzed
with the diagnostic kits, which were used in the plasma
analysis.
2.4. Hepatic Pathological Evaluation. Small pieces of hepatic
tissues taken from experimental animals were ﬁxed in 10%
neutral formalin, alcohol-dehydrated, paraﬃn-embedded,
and sectioned to a mean thickness of 4μm. The histolog-
ical examination by the above conventional methods was
evaluated for the index of diabetic-induced necrosis by
assessing the morphological changes with hematoxylin and
eosin (H&E) stain. Liver biopsy was scored according to
the criteria as follows: [20] grade 0, no steatosis, normal
liver; grade 1, <25% of hepatocytes aﬀected; grade 2, 26–
50% of hepatocytes aﬀected; grade 3, 51–75% of hepatocytes
aﬀected; grade 4, >76% of hepatocytes aﬀected.
2.5. Preparation of Hepatic Fractions. The hepatic tissue was
homogenized with ice-cold lysis buﬀer (pH 7.4) containing
137mmolL−1 NaCl, 20mmolL−1 Tris-HCl, 1% Tween 20,
10% glycerol, 1mmolL−1 phenylmethylsulfonyl ﬂuoride
(PMSF), and protease inhibitor mixture DMSO solution.
Thehomogenatewasthencentrifugedat2,000 ×g for10min
at 4◦C. The protein concentration of each fraction wasEvidence-Based Complementary and Alternative Medicine 3
Table 1:Changesonthebodyweight(BW),food,andwaterintakeinHFD-fedratsreceiving8-weektreatmentwithemodinorpioglitazone.
Groups Initial BW (g rat−1) BW gain (g rat−1) Food intake (g rat−1 per day) Water intake (mL rat−1 per day)
RCD-fed
Vehicle 172.5 ±7.7 17.8 ± 6.2b 19.3 ±5.97 7 .2 ±8.1
HFD-fed
Vehicle 173.4 ±6.95 3 .7 ±7.02 0 .3 ±6.78 6 .3 ±9.4
Emodin (mg kg−1 per day)
40 173.1 ±8.4 30.7 ± 6.9a 21.8 ±6.98 0 .8 ±9.7
80 172.8 ±6.7 23.6 ± 5.3b 20.3 ±6.37 8 .1 ±7.9
Pioglitazone (20mg kg−1 per day) 171.6 ±8.1 20.4 ± 5.8b 19.9 ±7.17 6 .7 ±8.9
Emodin or pioglitazone was dissolved in distilled water for oral administration at the desired doses in a volume of 2mL kg−1 once a day into HFD-fed rats.
The vehicle (distilled water) used to dissolve the tested medications was given at the same volume. Values (mean ± SEM) were obtained from each group of 8
animals in each group after 8 weeks of the experimental period. aP <. 05 and bP <. 01 compared to the values of vehicle-treated HFD-fed rats in each group,
respectively.
determined using a commercial kit (Bio-Rad Laboratories,
Hercules, CA, USA).
2.6. Western Blot Analyses. After homogenization of hepatic
tissue samples using a glass/Teﬂon homogenizer, protein
concentrations were determined using the BioRad protein
dye binding assay. The homogenates (50μg) were separated
by sodium dodecyl sulfate-polyacrylamide gel electrophore-
sis and Western blot analysis was performed using either
an anti-rat antibody to bind acetyl-CoA carboxylase (ACC)
(Santa Cruz Biotechnology, Inc., CA, USA; Cat. no. 3662),
phospho-ACC at Ser 79 (p-ACC; Cell Signaling Technol-
ogy, MA, USA), AMPKα (Cell Signaling Technology; Cat.
no. 2352), phospho-AMPKα at Thr 172 (p-AMPKα;C e l l
Signaling Technology; Cat. no. 2531), carnitine palmitoyl
transferase 1 (CPT-1; Cell Signaling Technology; Cat. no. sc-
98834), sterol regulatory element binding protein 1 (SREBP-
1; Santa Cruz Biotechnology, Inc.; Cat. no. sc-366), fatty
acid synthase (FAS; Cell Signaling Technology; Cat. no.
3180) or β-actin (Santa Cruz Biotechnology, Inc.; Cat.
no. sc-130656). Blots were incubated with the appropriate
peroxidase-conjugated secondary antibody. The membranes
were then washed three times in TBST (20mmol L−1 Tris-
HCl, pH 7.5), 150mmol L−1 NaCl, and 0.05% Tween 20
and visualized on X-ray ﬁlm using the enhanced chemilumi-
nescence detection system (Amersham Corp., Braunschweig,
Germany). Densitometric analysis of the bands for the
expression of protein was done with ATTO Densitograph
Software (ATTO Corporation, Tokyo, Japan).
2.7. Statistical Analysis. All data represented as the mean ±
SEM. Statistical diﬀerences among groups were determined
by using two-way repeated-measures ANOVA. The Dunnett
range post hoc comparisons were used to determine the
source of signiﬁcant diﬀerences where appropriate. A P value
<.05 was considered statistically signiﬁcant.
3. Results
3.1. Eﬀects on Body Weight (BW) and Feeding Behavior. The
BW gain was signiﬁcantly higher in HFD-fed rats than that
in the RCD-fed group (Table 1). Eight weeks after emodin
treatment, the BW gain of rats was signiﬁcantly lower than
that of rats in the HFD group. Emodin (80mg kg−1 per day)
signiﬁcantly suppressed BW gain; similar results were seen in
rats treated with pioglitazone (20mg kg−1 per day; Table 1).
Although the water intake became slightly higher in
vehicle-treated HFD-fed group as compared to the others,
no signiﬁcant diﬀerences were observed in daily food intake
among all the groups during whole experimental period
(Table 1).
3.2.EﬀectonPlasmaLipids. TheHFDcausedtheelevationof
plasma TC, TG, and LDL-c concentrations in rats (Table 2).
Emodin at the daily oral dosage of 40 and 80mg kg−1
signiﬁcantly decreased the level of plasma TC (23.5% and
31.6% reduction, resp.) in HFD-fed rats compared to their
vehiclecounterparts(Table 2).Alldosesofemodindecreased
the level of plasma TG in HFD-fed rats (Table 2). Emodin
at the daily oral dosage of 40 and 80mg kg−1 reduced
plasma levels of LDL-c by 38.2% and 52.1%, respectively,
(Table 2). Plasma TC, TG, and LDL-c concentrations were
signiﬁcantly lower by 38.4%, 47.3%, and 59.7%, respectively
in pioglitazone- (20mgkg−1 per day) treated HFD-fed rats
compared with vehicle-treated counterparts (Table 2).
Plasma level of HDL-c in HFD-fed rats was lower to
59.3% of that in the RCD-fed group (Table 2). After 8
weeks of treatment with emodin (80mg kg−1 per day) or
pioglitazone (20mg kg−1 per day), lower plasma level of
HDL-c in HFD-fed rats was elevated to nearly that of RCD-
fed group (Table 2).
The plasma FFAs were signiﬁcantly higher in HFD-fed
rats receiving vehicle (Table 2). After 8 weeks of treatment,
plasma FFA was lower by 37.5% in emodin- (80mg kg−1
per day) treated HFD-fed rats as compared with the vehicle-
treated counterparts (Table 2). FFA concentrations in HFD-
fed rats were signiﬁcantly lower by 46.3% in 8-weeks
pioglitazone-treated, HFD-fed rats compared to their vehicle
counterparts (Table 2).
Pioglitazone treatment arrested the elevation of AI and
CRI in HFD-fed rats (Table 2). Emodin administration also
caused a dose-related reduction in the atherogenic and
coronary artery risk indices in the HFD-fed rats when4 Evidence-Based Complementary and Alternative Medicine
Table 2: Changes in the plasma lipids, atherogenic index (AI), and coronary artery index (CRI) in HFD-fed rats receiving 8-weeks treatment
with emodin or pioglitazone.
Groups Plasma levels (mg dL−1)A I C R I
TC TG LDL-c HDL-c FFAs
RCD-fed
Vehicle 72.9 ± 5.8b 56.8 ±6.6b 31.8 ±3.2b 46.9 ± 3.4b 28.2 ±2.8b 0.7 ± 0.3b 1.6 ±0.4b
HFD-fed
Vehicle 130.2 ±12.3 128.5 ±6.3 120.2 ±4.22 7 .8 ±3.86 1 .9 ± 5.34 .3 ±0.24 .7 ±0.3
Emodin (mg kg−1 per day)
40 99.6 ± 8.3a 95.0 ± 5.2a 74.3 ± 5.1b 39.1 ±2.9a 47.1 ±3.8a 1.9 ± 0.1b 2.5 ± 0.3b
80 89.1 ± 7.9a 80.3 ±4.8b 68.1 ± 4.5b 43.9 ±3.2b 38.7 ±3.2b 1.6 ±0.1b 2.0 ± 0.3b
Pioglitazone (20mg kg−1 per day) 80.2 ±8.0b 65.6 ±4.7b 48.4 ± 4.3b 45.9 ±4.4b 33.2 ±4.1b 1.1 ±0.2b 1.7 ± 0.4b
Emodin or pioglitazone was dissolved in distilled water for oral administration at the desired doses in a volume of 2mL kg−1 once a day into HFD-fed rats.
The vehicle (distilled water) used to dissolve the tested medications was given at the same volume. Values (mean ± SEM) were obtained from each group of 8
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Figure 1: Changes in the hepatic cholesterol and triglyceride in
HFD-fed rats receiving 8-week treatment. Rats not receiving any
treatment were given the same volume of vehicle (distilled water)
used to dissolve the test medications. Hepatic lipids were analyzed
from vehicle-treated RCD-fed rats, vehicle-treated HFD-fed rats,
emodin- (40mg kg−1 p e rd a y )t r e a t e dH F D - f e dr a t s -( e m o d i n
40), emodin- (80mg kg−1 per day) treated HFD-fed rats (emodin
80) or pioglitazone (20mg kg−1 per day)-treated HFD-fed rats
(pioglitazone). Values (mean ± SEM) were obtained from each
group of 8 animals in each group after 8 weeks of the experimental
period. aP <. 05 compared to the values of vehicle-treated HFD-
f e dr a t si ne a c hg r o u p ,r e s p e c t i v e l y .
compared to the values recorded for the vehicle-treated
counterparts (Table 2).
3.3. Eﬀect of Treatment on Hepatic Lipids. The hepatic TC
level was signiﬁcantly higher in HFD-fed rats than that in
the RCD-fed group, those were lower by 35% in the 8-
weekemodin-(80mgkg−1 perday)treatedgroup(Figure 1).
HFD-fed rats receiving 8-week treatment with emodin-
(80mg kg−1 per day) also showed signiﬁcantly lower values
of hepatic TG to 64.7% as compared with the vehicle-
treated counterparts (Figure 1). Hepatic TC and TG levels in
HFD-fed rats were signiﬁcantly lower by 44.3% and 43.8%,
respectively, in pioglitazone-treated rats compared to their
vehicle-counterparts (Figure 1).
3.4. Morphological Changes in Hepatocytes. HFD-fed rats
showed considerable hepatic lipid accumulation compared
with that in RCD-fed group (Figure 2). After 8 weeks, the
extent of hepatic lipid accumulation in pioglitazone-treated
HFD-fedratswassimilartothoseinRCD-fedrats(Figure 2).
The pathological grading of hepatic steatosis in HFD-fed
rats was 3.1 ± 0.6, which was decreased to 1.7 ± 0.5i n
pioglitazone-treated group. HFD-fed rats receiving 8-week
treatment with emodin showed considerably lower hepatic
lipid accumulation than in their vehicle-treated counterparts
(Figure 2). The pathological grading of hepatic steatosis in
HFD-fed rats was reduced to 2.7 ± 0.4a n d2 .0 ± 0.8a f t e r
receiving an 8-week treatment with emodin at the daily dose
of 40 or 80mg kg−1,r e s p e c t i v e l y .
3.5. Protein Expression and Phosphorylation of AMPK and
ACC in Hepatocytes. The immunoblot results showed that
the HFD led to a decrease in the protein levels and phospho-
rylation degree of AMPK in the hepatocytes as compared to
theRCD-fedrats(Figure 3).Similarly,boththeproteinlevels
and phosphorylation degree of ACC in the hepatocytes of
HFD-fed rats were downregulated than those of the RCD-
fed group (Figure 3). Furthermore, the HFD signiﬁcantly
reduced the phospho-AMPK/AMPK ratio (by 51.8% relative
to those in vehicle-treated HFD-fed rats, P<. 05) and
the phospho-ACC/ACC ratio (by 46.7% relative to those in
vehicle-treated HFD-fed rats, P<. 05) in the hepatocytes
of the rats (Figure 3). These HFD-induced downregulations
in the ratio of phospho-AMPK/AMPK and the phospho-
ACC/ACCweresigniﬁcantlyreversedinthehepatocytesafter











Figure 2: Histopathological ﬁndings in livers of HFD-fed rats receiving 8-week treatment. Rats not receiving any treatment were given the
same volume of vehicle (distilled water) used to dissolve the test medications. Photomicrographs are of tissues isolated from vehicle-treated
RCD-fed rats (vehicle-RCD), vehicle-treated HFD-fed rats (vehicle-HFD), emodin- (40mgkg−1 per day) treated HFD-fed rats- (emodin
40-HFD), emodin (80mgkg−1 per day) treated HFD-fed rats (emodin 80-HFD) or pioglitazone- (20mgkg−1 per day) treated HFD-fed rats
(pioglitazone-HFD). Photomicrographs were taken at a magniﬁcation of x400.
and59.2%increasesrelativetothoseinvehicle-treatedHFD-
fed rats, respectively; P<. 05) (Figure 3). Treatment of HFD-
fed rats with pioglitazone also signiﬁcantly upregulated the
ratioofphospho-AMPK/AMPKandthephospho-ACC/ACC
in the hepatocytes to 1.7-fold and 1.6-fold relative to those in
vehicle-treated HFD-fed rats (P<.05, Figure 3).
3.6. Protein Expression of SREBP-1, FAS, and CPT-1 in Hep-
atocytes. The immunoblot results showed that the protein
expressions of hepatic SREBP-1 and FAS in HFD-fed rats
were higher than those of RCD-fed group (Figure 4). The
HFD-fed rats treated with pioglitazone for 8 weeks had
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Figure 3: Representative immunoblots of hepatic protein levels
and phosphorylation degrees of AMPK and ACC in HFD-fed
rats receiving 8-week treatment. Rats not receiving any treatment
were given the same volume of vehicle (distilled water) used to
dissolve the test medications. Immunoblots are of tissues isolated
from vehicle-treated RCD-fed rats, vehicle-treated HFD-fed rats,
emodin- (40mg kg−1 p e rd a y )t r e a t e dH F D - f e dr a t s( e m o d i n
40), emodin- (80mg kg−1 per day) treated HFD-fed rats (emodin
80) or pioglitazone- (20mg kg−1 per day) treated HFD-fed rats
(pioglitazone). Similar results were obtained with an additional
4 replications. Phospho-AMPK/AMPK and phospho-ACC/ACC
protein expression were expressed as mean with SEM (n = 5p e r
group) in each column. aP <. 05 and bP <. 01 compared to the
values of vehicle-treated HFD-fed rats.
lower than those in vehicle-treated counterpart (P<.05,
Figure 4). Hepatic SREBP-1 protein expression levels in
HFD-fed rats after 8-week treatment with emodin (80mg
kg−1 per day) were decreased by 31.6% relative to expression
levelsinvehicle-treatedHFD-fedrats(P<. 05,Figure 4).The
HFD-induced increase in the hepatic FAS protein expression
was also reversed by feeding the rats with the emodin (80mg
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Figure 4: Representative immunoblots of hepatic protein levels
of SREBP-1, FAS, and CPT-1 in HFD-fed rats receiving 8-week
treatment. Rats not receiving any treatment were given the same
volume of vehicle (distilled water) used to dissolve the test
medications. Immunoblots are of tissues isolated from vehicle-
treated RCD-fed rats, vehicle-treated HFD-fed rats, emodin (40mg
kg−1 per day)-treated HFD-fed rats (emodin 40), emodin- (80mg
kg−1 per day) treated HFD-fed rats (emodin 80), or pioglitazone-
(20mg kg−1 per day) treated HFD-fed rats (pioglitazone). Similar
results were obtained with an additional 4 replications. Protein
levels are expressed as the mean with SEM (n = 5 per group) in
each column. aP <. 05 and bP <. 01 compared to the values of
vehicle-treated HFD-fed rats in each group, respectively.
relative to those in vehicle-treated HFD-fed rats, resp.; P<
.05).
The immunoblot results showed that the hepatic protein
levels of CPT-1 in HFD-fed rats were lower than those
of RCD-fed group (P<. 05, Figure 4). The HFD-fed rats
treated with pioglitazone for 8 weeks had hepatic CPT-1
protein levels that were approached to those in the RCD-
fed group (Figure 4). Administration HFD-fed rats with
emodin (80mg kg−1 per day) also signiﬁcantly upregulatedEvidence-Based Complementary and Alternative Medicine 7
the hepatic protein level of the CPT-1 to 2.4-fold relative to
those in vehicle-treated HFD-fed rats (P<. 05, Figure 4).
4. Discussion
Obesity, especially abdominal obesity, has an association
with dyslipidemia characterized by increasing TG and
decreasing HDL-c concentrations [21]. Compelling evi-
dence, from meta-analysis of a number of clinical studies
on a large aggregate of patients, has established an increased
level of TG as an independent risk factor for cardiovascular
disease [22]. TG is involved in the ectopic accumulation of
lipid stores in the liver and is associated with a number of
diseases such as metabolic syndrome and type 2 diabetes.
High TC levels increase the risk of developing coronary
heart disease, and high levels of HDL-c are also a risk factor
for coronary heart disease, while high HDL-c is helpful in
transporting excess cholesterol to the liver for excretion in
the bile [23]. As a result, HDL-c levels are inversely related
to this risk [24]. The present study demonstrated that HFD-
fed rats showed a signiﬁcant increase in plasma TC, TG,
and LDL-c levels. However, levels of plasma HDL-c in HFD-
fed rats were decreased compared with the RCD-group.
Similar to pioglitazone treatment, emodin (80mg kg−1 per
day) signiﬁcantly lowered plasma TC, TG and LDL-c levels
in rats with HFD-induced obesity. The eﬀect of emodin
administration on the atherogenic and coronary artery risk
indices is notable.
A large body of evidence indicates that AMPK is involved
inthemaintenanceoflipidandcholesterolhomeostasis[10].
Activation of hepatic AMPK (through phosphorylation of its
α-subunitonThr172)switchesoﬀfattyacidsynthesisacutely
via increased phosphorylation and inactivation of ACC
which reduces the production of malonyl-CoA, an allosteric
inhibitor of CPT-1 [25]. CPT-1, regulating acyl-CoA inﬂow
and β-oxidation in the mitochondrial outer membrane, is a
rate-limiting step for fatty acid oxidation [25]. Inactivation
of ACC by AMPK helps promote fatty acid utilization, lead-
ing to fat burning in fat and muscle. The study was further
to clarify whether the action of emodin on the regulation
of lipid disorders is related with AMPK-signaling pathway.
The results showed that, concomitant with enhancement
of AMPK activity by promoting AMPK phosphorylation,
and inhibition of ACC activation by increasing ACC phos-
phorylation, emodin up-regulated CPT-1 gene expression in
hepatocytes, suggesting that emodin may reduce lipid levels
via promotion of hepatic fatty acid oxidation mediated by
regulating AMPK activation.
Sterol regulatory element binding protein 1 (SREBP-
1) is a key lipogenic transcription factor, which directly
activates the expression of more than 30 genes (including
FAS), dedicated to the synthesis and uptake of fatty acids,
cholesterol, and triglyceride [26]. Increased SREBP-1 levels
have been found in patients with histologically diagnosed
NAFLD [27], and in the fatty livers of obese (ob/ob) mice
[28] and obese rats induced by fat-diet feeding [29]. It
is known that SREBP-1 is negatively regulated by AMPK















Figure 5: The possible mechanisms of emodin action on the
regulation of lipid metabolism in liver of HFD-fed rats.
ofSREBP-1andFAScausedbyHFD,implyingthatactivation
of AMPK stimulated by emodin may lead to prevent SREBP-
1translocationtothenucleianddownregulationofSREBP-1
and FAS expression as well, ﬁnally leading to inhibit hepatic
lipogenesis. These ﬁndings may provide molecular evidence
for the use of emodin as a therapy for the management of
NAFLD.
Emodin is a potent PPARγ agonist that could render
it as an attractive therapeutic agent for managing diabetes
mellitus which has been documented [9]. The antidiabetic
and lipid-modulating eﬀects of emodin involved in the
upregulation of L-type calcium channel expression in the
pancreas and heart in dyslipidaemic-diabetic rats have also
been demonstrated [31]. This study reports, for the ﬁrst
time, emodin could decrease lipid synthesis and increase
fatty-acid oxidation through activating AMPK, which fur-
ther inhibits protein expression in SREBP-1 and lead to
the downregulation of FAS, as well as reduction of the
transcription activity of ACC and in turn enhancement
CPT-1 gene expression (Figure 5). These results together
with the previous observations that emodin may possess
multi-functional activities against dyslipidemia as well are of
importance.
In conclusion, the results of this study showed that
emodin enhances CPT-1 expression along with increased
AMPK and ACC protein expression and phosphorylation in
hepatocytes of HFD-fed rats. The results also indicate that
the activation of the AMPK-signaling pathway may play a
critical role in the suppression eﬀect of emodin on SREBP-
1c and FAS. These ﬁndings may provide molecular evidence
for the use of emodin as a therapy for the management of
hyperlipidaemia and/or fatty liver.8 Evidence-Based Complementary and Alternative Medicine
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